Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

Choosing Wisely: ctDNA/ Precision Oncology in colorectal cancers

ESMO 2025: Latest developments in endometrial cancer

ESMO 2025: Highlights and analysis

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T ce may reduce toxicity in older lymphoma patients

Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma

High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma

Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD

KRdc as induction therapy shows improved OS for NDMM patients

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM